Xenograft and organoid model systems in cancer research

TY - JOUR

T1 - Xenograft and organoid model systems in cancer research

AU - Bleijs, Margit

AU - van de Wetering, Marc

AU - Clevers, Hans

AU - Drost, Jarno

N1 - © 2019 The Authors. Published under the terms of the CC BY 4.0 license.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Patient-derived tumour xenografts and tumour organoids have become important preclinical model systems for cancer research. Both models maintain key features from their parental tumours, such as genetic and phenotypic heterogeneity, which allows them to be used for a wide spectrum of applications. In contrast to patient-derived xenografts, organoids can be established and expanded with high efficiency from primary patient material. On the other hand, xenografts retain tumour-stroma interactions, which are known to contribute to tumorigenesis. In this review, we discuss recent advances in patient-derived tumour xenograft and tumour organoid model systems and compare their promises and challenges as preclinical models in cancer research.

AB - Patient-derived tumour xenografts and tumour organoids have become important preclinical model systems for cancer research. Both models maintain key features from their parental tumours, such as genetic and phenotypic heterogeneity, which allows them to be used for a wide spectrum of applications. In contrast to patient-derived xenografts, organoids can be established and expanded with high efficiency from primary patient material. On the other hand, xenografts retain tumour-stroma interactions, which are known to contribute to tumorigenesis. In this review, we discuss recent advances in patient-derived tumour xenograft and tumour organoid model systems and compare their promises and challenges as preclinical models in cancer research.

U2 - 10.15252/embj.2019101654

DO - 10.15252/embj.2019101654

M3 - Article

C2 - 31282586

SN - 0261-4189

VL - 38

SP - e101654

JO - EMBO Journal

JF - EMBO Journal

IS - 15

ER -